Advertisement

3 Biotech

, 8:278 | Cite as

l-Asparaginase: a feasible therapeutic molecule for multiple diseases

  • Archana Vimal
  • Awanish Kumar
Letter to the Editor
  • 82 Downloads

Abstract

This note highlights our understanding and thinking about the feasibility of l-asparaginase as therapeutics for multiple diseases. l-asparaginase enzyme (l-asparagine amidohydrolase, EC 3.5.1.1) is prominently known for its chemotherapeutic application. It is primarily used in the treatment of acute lymphoblastic leukemia in children. It is also used in the treatment of other forms of cancer Hodgkin disease, lymphosarcoma, acute myelomonocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma (Lopes et al. Crit Rev Biotechnol 23:1–18, 2015). It deaminates l-asparagine present in the plasma pool causing the demise of tumor cell due to nutritional starvation. The anti-tumorigenic property of this enzyme has been exploited for over four decades and evidenced as a boon for the cancer patients. Presently, the medical application of l-asparaginase is limited only in curing various forms of cancer.

Keywords

l-asparaginase Malignance Autoimmune disease Infectious disease Therapeutic 

Notes

Acknowledgements

Authors are thankful to National Institute of Technology, Raipur (CG), India for providing facility, space and resources for this work.

Compliance with ethical standards

Conflict of interest

The authors have declared no conflict of interest.

References

  1. Baruch M, Belotserkovsky I, Hertzog BB et al (2014a) An extracellular bacterial pathogen modulates host metabolism to regulate its own sensing and proliferation. Cell 156:97–108.  https://doi.org/10.1016/j.cell.2013.12.007 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Baruch M, Hertzog BB, Ravins M et al (2014b) Induction of endoplasmic reticulum stress and unfolded protein response constitutes a pathogenic strategy of group A streptococcus. Front Cell Infect Microbiol 4:1–5.  https://doi.org/10.3389/fcimb.2014.00105 CrossRefGoogle Scholar
  3. Eckhardt M, Barth H, Blo D, Aktories K (2000) Binding of clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. J Biol Chem 275:2328–2334CrossRefPubMedGoogle Scholar
  4. Gesbert G, Ramond E, Rigard M et al (2014) Asparagine assimilation is critical for intracellular replication and dissemination of Francisella. Cell Microbiol 16:434–449.  https://doi.org/10.1111/cmi.12227 CrossRefPubMedGoogle Scholar
  5. Gieldanowski J (1976) Studies on the immunosuppressive and anti-inflammatory action of L-asparaginase. Arch Immunol Ther Exp (Warsz) 24:243–247Google Scholar
  6. Lopes AM, Oliveira-nascimento L, Ribeiro A et al (2015) Therapeutic l-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol 23:1–18.  https://doi.org/10.3109/07388551.2015.1120705 CrossRefGoogle Scholar
  7. Reiff A, Zastrow M, Sun BC et al (2001) Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol 19:639–646PubMedGoogle Scholar
  8. Saba CF, Hafeman SD, Vail DM, Thamm DH (2009) Combination chemotherapy with continuous l-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. J Vet Intern Med 23:1058–1063CrossRefPubMedGoogle Scholar
  9. Saito A, Ochiai K, Kondo S et al (2011) Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 286:4809–4818.  https://doi.org/10.1074/jbc.M110.152900 CrossRefPubMedGoogle Scholar
  10. Vimal A, Kumar A (2017) In vitro screening and in silico validation revealed key microbes for higher production of significant therapeutic enzyme l-asparaginase. Enzyme Microb Technol 98:9–17.  https://doi.org/10.1016/j.enzmictec.2016.12.001 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of BiotechnologyNational Institute of Technology (NIT)RaipurIndia

Personalised recommendations